FOCUS PHARMA
The computed 12-month bankruptcy probability of FOCUS PHARMA is 0.5% (low). The company has been active since 2012 and the Belgian State Gazette contains no insolvency or warning signals. No processed annual-account figures are available; this conclusion rests on registry and State Gazette data only.
| Active | 14 yrs |
| Locations | 1 |
| Publications | 1 |
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
| Fiscal year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2024 | micro | 14-07-2025 | 2025-00281023 |
| 31-12-2023 | micro | 25-07-2024 | 2024-00297065 |
| 31-12-2022 | micro | 12-07-2023 | 2023-00237953 |
| 31-12-2021 | micro | 22-06-2022 | 2022-20081315 |
| 31-12-2020 | micro | 25-06-2021 | 2021-25300565 |
| 31-12-2019 | micro | 31-07-2020 | 2020-37500590 |
| 31-12-2018 | micro | 18-07-2019 | 2019-34300068 |
| 31-12-2017 | micro | 13-08-2018 | 2018-45500299 |
| 31-12-2016 | micro | 07-07-2017 | 2017-28900316 |
| 31-12-2015 | verkort | 23-08-2016 | 2016-46400524 |
| NACE primary | Wholesale trade(46460) |
| Legal form | Public limited company(014) |
| Incorporation | 19-06-2012 |
| Status | Active |
| Postal code | 3001 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 24514C0086/00N000 | Flanders | 9,445 m² | 1 · 412 m² | 7.3 m · 2 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
06-11-2024 3 directors appointed
- Peter Van Ruyskensvelde, Gedelegeerd bestuurder
- Peter Van Ruysvelde, Bestuurder
- Peter Van Ruysvelde, Bestuurder
Technical details
{
"events": [
{
"kind": "director_in",
"role": "gedelegeerd_bestuurder",
"person": {
"rrn": null,
"name": "Peter Van Ruyskensvelde",
"address": "Molenheidebaan 125, 3191 Hever",
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "renewal",
"via_org": null,
"statutory": "statutair",
"compensated": null,
"effective_date": "2024-05-29",
"evidence_quote": "Het bestuursorgaan beslist, met ingang van 29/05/2024, Peter Van Ruyskensvelde, wonende te Molenheidebaan 125, 3191 Hever, te (her)benoemen tot gedelegeerd bestuurder: bevoegd tot daden van dagelijks bestuur, overeenkomstig artikel 11 van de statuten \u00E9n met de volledige externe vertegenwoordigingsbe",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": "immediate"
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Peter Van Ruysvelde",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "renewal",
"via_org": null,
"statutory": "statutair",
"compensated": false,
"effective_date": "2024-05-29",
"evidence_quote": "De algemene vergadering beslist als bestuurder te herbenoemen: Peter Van Ruysvelde. Zijn mandaat gaat in op 29/05/2024 en heeft een bepaalde duur van 6 jaar en zal dus behoudens herverkiezing eindigen op 29/05/2030. Het mandaat van de zopas benoemde bestuurder is onbezoldigd, tenzij anders beslist d",
"decharge_status": null,
"mandate_duration": {
"kind": "n_years",
"value": "6"
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": "immediate"
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Peter Van Ruysvelde",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "renewal",
"via_org": null,
"statutory": "statutair",
"compensated": false,
"effective_date": "2024-05-29",
"evidence_quote": "De algemene vergadering beslist als bestuurder te herbenoemen: Peter Van Ruysvelde. Zijn mandaat gaat in op 29/05/2024 en heeft een bepaalde duur van 6 jaar en zal dus behoudens herverkiezing eindigen op 29/05/2030. Het mandaat van de zopas benoemde bestuurder is onbezoldigd, tenzij anders beslist d",
"decharge_status": null,
"mandate_duration": {
"kind": "n_years",
"value": "6"
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": "immediate"
},
{
"kind": "substantive_delegation",
"role": null,
"person": null,
"reason": null,
"subkind": null,
"via_org": {
"kbo": "0451.657.041",
"name": "Moore Finance \u0026 Tax BV",
"address": "Buro \u0026 Design Center, Esplanade 1 bus 96, 1020 Brussel",
"country": "BE",
"legal_form": "BV"
},
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "Een bijzondere volmacht wordt verleend aan Moore Finance \u0026 Tax BV, ingeschreven met ondernemingsnummer 0451.657.041 en gekend op de Nederlandstalige Ondernemingsrechtbank Brussel, met zetel te Buro \u0026 Design Center, Esplanade 1 bus 96, 1020 Brussel, alsook aan al haar bedienden, aangestelden en lasth",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": "Leuven",
"is_associated": false
},
"act_meta": {
"language": "nl",
"pub_date": "2024-11-06",
"filing_date": "2024-10-28",
"act_kind_objet": "Onderwerp akte:"
},
"decisions": [
{
"body": "algemene_vergadering",
"date": "2024-05-29",
"unanimous": true
},
{
"body": "algemene_vergadering",
"date": "2024-05-29",
"unanimous": true
},
{
"body": "bijzondere_algemene_vergadering",
"date": "2024-05-29",
"unanimous": true
}
],
"is_correction": false,
"subject_company": {
"kbo": "0846.744.870",
"name_full": "FOCUS PHARM\u0410",
"legal_form": "NV"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Margarete Swinnen",
"org_rep_person_name": null,
"person_role_at_subject": "Gevolmachtigde"
},
"co_filed_documents": [
"Notulen van de algemene vergadering dd. 29/05/2024",
"Verslag van gedelegeerde bestuurders na afsluiting van de algemene vergadering van 29/05/2024"
],
"corrected_publication_numac": null
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameNL | FOCUS PHARMA |